International
White House Withdraws Heidi Overton’s FDA Nomination Amid Senate Opposition
The White House has withdrawn the nomination of Dr. Heidi Overton to lead the United States Food and Drug Administration (FDA), after mounting political opposition raised doubts about her chances of securing Senate confirmation.
The decision was announced on Tuesday, November 17, 2026, a day before the Senate Health, Education, Labor and Pensions Committee was scheduled to vote on her nomination.
Overton, a physician and former deputy director of the White House Domestic Policy Council, was nominated by President Donald Trump in August to head the agency responsible for regulating medicines, vaccines, tobacco products and much of the US food supply.
Her nomination, however, faced scrutiny from both Republican and Democratic lawmakers over her position on vaccine policy and whether she could maintain scientific independence from the White House.
Republican Senator Bill Cassidy of Louisiana, who chairs the Senate health committee, had previously expressed strong reservations about Overton’s support for the administration’s proposal to separate combination childhood vaccines, including the measles, mumps and rubella (MMR) vaccine.
Cassidy questioned her during a September confirmation hearing about whether she would be willing to challenge Trump and Health Secretary Robert F. Kennedy Jr. when scientific evidence contradicted their positions.
Other Republican lawmakers, including Senator Susan Collins of Maine, also raised concerns about Overton’s approach to flavoured electronic cigarettes, particularly products that could appeal to young people.
Her nomination also attracted criticism from influential supporters of the Make America Healthy Again (MAHA) movement, who questioned her commitment to some of Kennedy’s health policy priorities.
However, Cassidy offered a different explanation following the withdrawal, suggesting that Overton could have secured sufficient support to advance through the committee and the full Senate.
In a statement shared on social media, he said the administration withdrew her nomination rather than provide assurances demanded by some anti-abortion Republicans on abortion-related policy issues.
The disagreement comes as the FDA is conducting a safety review of mifepristone, a commonly used abortion medication, following a request from Trump. The agency is expected to report its findings by March 2027.
Overton’s withdrawal represents another setback for the Trump administration’s efforts to install its preferred leadership at major public health agencies.
Trump previously replaced his first nominee to lead the Centers for Disease Control and Prevention, Dr. David Weldon, after questions emerged about his prospects for confirmation. Two of the administration’s surgeon general nominees have also faced withdrawals following opposition from lawmakers.
The FDA is currently being led by acting commissioner Kyle Diamantas, who previously served as the agency’s top food official.
It remains unclear when the White House will nominate another candidate to lead the agency permanently.
